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Abstract
Background: Cerebrovascular disorders have occurred more frequently in some Central Nervous System (CNS)
disorders, such as epilepsy. Some CNS drugs have been associated with increased stroke risk. Our aim was to
estimate the risk of ischaemic stroke in patients exposed to antiepileptic drugs (AED).
Methods: Population-based matched case-control study using SIDIAP database, based in electronic health records
from primary healthcare from Catalonia, Spain. Cases were those patients with a registered diagnosis of first stroke
during 2009–2014. Up to 10 controls were selected for each case and matched by sex, age, and geographic area
and without a prior diagnosis of stroke. We considered global drug exposure to AED, past and current exposure
and exposure in monotherapy to each AED.
Results: 2,865 cases and 19,406 controls were exposed to AED during the study period. Global exposure to
levetiracetam [(ORadj3.3, CI95 % 2.8-4.0)], phenytoin [ORadj1.5, CI95 % 1.2–41.9)], and valproic acid [(ORadj 1.3, CI95 %
1.1–1.6)], showed significantly association to ischaemic stroke that was also maintained with current exposure of
levetiracetam [ORadj4.1, CI95 % 3.3–5.2)] and valproic acid [ORadj1.4, CI95 % 1.1–1.9)]. Current levetiracetam
monotherapy showed a very high risk of ischaemic stroke [(ORadj 5.1, CI95 % 3.7–6.9)].
Conclusions: Drugs used for other conditions than epilepsy (pregabalin, gabapentin) were the most used AED and
both did not show a risk. Levetiracetam shows a risk for stroke even when assessed in current monotherapy. The
lack of data regarding the link with diagnosis and severity in our study makes it necessary to conduct further
studies to confirm or dismiss our results, focussing on levetiracetam.
Keywords: Antiepileptic drugs, Stroke, Drug exposure, Electronic health records, Primary healthcare
Background
Stroke is the second leading cause of death worldwide
[1]. There are four types: ischaemic stroke, primary
intracerebral haemorrhage, subarachnoid haemorrhage
and undefined, being the ischaemic type the most fre-
quent one (80–85 %) in Caucasian population [2, 3].
Stroke patients are at highest risk of death in the first
weeks after the event, and between 20 and 50 % die
within the first month depending on type, severity, age,
comorbidity and effectiveness of treatment of complica-
tions. Those who survive can remain with or without
disabilities, such as loss of speech and movement, mak-
ing strokes the third cause of disability [1]. Over the last
decades the total number of age-standardized rates of
stroke mortality have decreased meanwhile stroke survi-
vors have made the burden of stroke Disability-Adjusted
Life Year (DALY lost) increase [2].
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The pooled proportional frequency of ischaemic stroke
in 2000–2008 was lower in low to middle income coun-
tries than in high-income countries (67 and 82 %, re-
spectively) [2]. In high income countries in 2000–2008,
early (21 days to 1 month) case fatality was between 13
and 23 %, [2] being in Catalonia mortality rate standard-
ized by age 29.2 deaths/100,000 inhabitants in 2016 [4].
The most important modifiable risk factors for ischae-
mic stroke are hypercholesterolemia, hypertension, dia-
betes and smoking [5, 6].
Cerebrovascular disorders have occurred more fre-
quently in some Central Nervous System (CNS) disor-
ders, such as epilepsy [7–10] and also some CNS drugs
have been reported to increase the risk for stroke, such
as antidepressants, [11] anti-dementia drugs, [12] anti-
psychotics [13, 14] or antiepileptic drugs (AED) [15–17].
The mechanism suggested for AED is that they would
increase risk of vascular diseases by accelerating athero-
sclerosis; for example cytochrome P450 enzyme-
inducing AED as carbamazepine increase serum levels of
total cholesterol and LDL-cholesterol and lipoprotein
[16]. Concurrently, AED are often administered after a
stroke to treat seizures or other conditions [18–20].
As there has been an increase in the chronic use of
AED, on account of its use for the treatment of diseases
different from epilepsy, like chronic neuropathic pain,
migraine, anxiety and as mood stabilizers, [21] we think
it is relevant to confirm if the risks detected in other
studies are confirmed in our population. The aim of this
study was to estimate the risk of ischaemic stroke in pa-
tients exposed to AED.
Methods
Study design
Population-based matched case-control study using data
from primary healthcare (PHC) electronic records.
Study source
Information System for Research in Primary Care (SIDI
AP) database; which contains data from 279 PHC cen-
tres from the Catalan Health Institute (ICS), covering
5.8 million people (80 % of the Catalan population) [22].
SIDIAP contains anonymized clinical information origi-
nated from different data sources: (1) ECAP (electronic
health records in PHC of the ICS), including information
since 2006 on sociodemographic characteristics, health
conditions registered as International Classification Dis-
eases Tenth Revision (ICD-10) [23] code, general practi-
tioners’ (GP) prescriptions, clinical parameters and toxic
habits, (2) laboratory data, (3) pharmacy invoice data
corresponding to GP’s prescriptions (available since
2005) including information on all pharmaceutical prod-
ucts dispensed by communities pharmacies with Catalan
Health System prescriptions by Anatomic Therapeutic
and Chemical (ATC) [24] codes, and 4), Minimum Data
Set at Hospital Discharge (CMBD-HA) [25] database for
ICS hospitals, including diagnoses at hospital discharge
registered as International Classification Diseases, Ninth
Revision (ICD-9) codes [26].
Selection of cases and controls
Cases were those patients ≥ 18 years old suffering a first
ischaemic stroke (CMBD-HA hospital admission ICD
9th codes: 433, 434, 435, 436, 437, 438) during 2009–
2014 attended in hospitals from the ICS in Catalonia,
Spain. Index date was the day of hospital admission for a
stroke from January 2009 to December 2014.
A total of 10 controls were selected for each case, and
matched by sex, age (+/- 1 year), geographic area and
without previous diagnosis of stroke; any historic record
of stroke before the selection year caused the exclusion
as a control. The index date for controls was the same
than for their respective case.
Variables
Age, sex, socioeconomic index (MEDEA) [27], body
mass index (BMI), smoking status, alcohol intake, co-
morbidities, cardiovascular risk (classified as high, mod-
erate, low or no risk), laboratory data including
glomerular filtration rate (GFR) calculated per MDRD
(Modification of Diet in Renal Disease), drug exposure
and number of visits in PHC during the previous year to
the index date.
Patients diagnosed with ischaemic heart disease and/or
peripheral artery disease and/or diabetes with complica-
tions were classified with a high cardiovascular risk.
Among the unclassified patients in the high category,
those with uncomplicated diabetes, treatment with anti-
diabetic drugs or two or three of the following diagno-
ses: dyslipidaemia, hypertension, and smoking (active or
ex-smoking) were classified as moderate cardiovascular
risk. Patients who were not classified in any category
were considered to be at low cardiovascular risk (divided
into two groups: very low cardiovascular risk if no risk
factors registered and low cardiovascular risk if one risk
factor registered).
Exposure definition
The drugs of interest were antiepileptics, N03A from the
ATC classification. Information of exposure was ob-
tained from GP’s prescriptions and pharmacy invoice
data. Current comedications before index date were also
collected: anticoagulants, antiplatelets, diabetes and
cardiac therapy, lipid modifying agents, hormonal con-
traceptives, non-steroidal anti-inflammatory drugs
(NSAID), analgesics, and psychotropic drugs.
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As first SIDIAP registers begin in 2005, a minimum
period of four years was selected in order to assess the
AED exposure.
We considered drug exposure when there was a dis-
pensation of at least three packages of an active sub-
stance of any of the study drugs (AED) during the study
period. Past exposure was considered if the dispensation
had taken place more than one year before the index
date. Current exposure was considered if patients had at
least one dispensation within the three months before
the index date. Trying to avoid indication bias, patients
with one dispensation within the same month of the
index date were excluded for the current exposure ana-
lysis. Also, current exposure to only one AED was also
ascertained as monotherapy exposure.
Population size
For the study period SIDIAP had around 40,000 patients
with a new stroke diagnosis registered. As CMBD-HA
represents about a third of the SIDIAP total population
(ICS hospitals and their primary care referral areas), we
aimed to include approximately 12,000 cases. Assuming
that the prevalence of exposure to the studied factors
would be 1 % higher in cases, the available sample size
would allow for detecting significant associations with
OR ≥ 1.3 with a type I error of 5 % and an 80 % power.
Statistical analysis
We conducted multivariate models of conditional logis-
tic regression, and we calculated crude and adjusted
odds ratios (OR, ORadj) and their 95 % confidence inter-
val (CI 95 %). The crude model adjusted by age, sex, year
of the index date and cardiovascular risk. The variables
used in the adjusted model were: age, sex, year of the
index date, MEDEA index, BMI, smoking status, number
of visits to PHC, GFR, and diagnoses of: arthrosis, de-
mentia, depression, diabetes, dyslipidaemia, epilepsy,
fibromyalgia, hypertension, ischaemic heart disease,
neuropathy, peripheral arterial disease and gastrointes-
tinal ulcer. Co-treatments (insulin, antihypertensive
drugs, NSAID…) and all study drugs included were
added in this model.
We estimated the crude and adjusted effects of the
current, past and global exposure to AED, and the effect
of each AED for patients exposed in monotherapy.
Results
A total of 137,880 patients were included in the study;
they were 12,616 cases with a first ischaemic stroke dur-
ing 2009–2014 matched by sex, age and geographical re-
gion with 125,264 controls with no stroke history
(Fig. 1). There were 56.3 % of men and their mean age
was 72.6 (SD 13.2). Their baseline sociodemographic
and clinical characteristics are described in Table 1 and
their comedications at baseline, in Table 2. Cases and
controls were different in most baseline characteristics
highlighting the neuromental illness such as dementia
(cases n = 828, 6.6 % and controls n = 6075, 4.8 %,), de-
pression (853, 6.8 6870, 5.5) and epilepsy (cases n = 207,
1.6 % and controls n = 843, 0.7 %) and also in their
Fig. 1 Study flowchart
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Table 1 Sociodemographic and clinical characteristics at baseline of patients exposed to Central Nervous System drugs
N, % Total N = 137,880 Cases N = 12,616 Controls N = 125,264 p-value
Mean age, SD 72.6, 13.2 72.9, 13.2 72.6, 13.2 0.009
Sex, female 60216, 43.7 5486, 43.5 54730, 43.7 0.658
N visits in PHC
Missing values 15165, 11.0 682, 5.4 14483, 11.6 <0.001
<5 27055, 22.0 1860, 15.6 25195, 22.7 <0.001
5-9 33155, 27.0 2460, 20.6 30695, 27.7
10-24 46191, 37.6 4837, 40.5 41354, 37.3
≥25 16314, 13.3 2777, 23.3 13537, 12.2
Smoking status
Missing values 18895, 13.7 1294, 10.3 17601, 14.1 <0.001
Current smokers 16172, 13.6 2020, 17.8 14152, 13.1 <0.001
BMI mean, SD 28.9, 4.7 28.8, 4.9 28.9, 4.7 0.273
Missing values 78443, 56.9 6610, 52.4 71833, 57.3 <0.001
Obesity 21708, 36.5 2180, 36.3 19528, 36.5 <0.001
MEDEA <0.001
U 8431, 6.1 1216, 9.6 7215, 5.8
R 25909, 18.8 2343, 18.6 23566, 18.8
U1-U3 58111, 42.1 4955, 39.3 53156, 42.4
U4-U5 45429, 32.9 4102, 32.5 41327, 33.0
GFR
Missing values 56401, 40.9 4186, 33.2 52215, 41.7 <0.001
<30 mL/min/1.73m2 1599, 2.0 311, 3.7 1288, 1.8 <0.001
30-44 5357, 6.6 802, 9.5 4555, 6.2
45-59 12751, 15.6 1568, 18.6 11183, 15.3
≥60 61772, 75.8 5749, 68.2 56023, 76.7
Cardiovascular risk, high 14978, 10.9 2511, 19.9 12467, 10.0 <0.001
Comorbidities
Anxiety 12792, 9.3 1177, 9.3 11615, 9.3 0.836
Arthrosis 31921, 23.2 2823, 22.4 29098, 23.2 0.031
Cancer 24479, 17.8 2306, 18.3 22173, 17.7 0.106
COPD 16594, 12.0 1822, 14.4 14772, 11.8 <0.001
Dementia 6903, 5.0 828, 6.6 6075, 4.8 <0.001
Depression 7723, 5.6 853, 6.8 6870, 5.5 <0.001
Diabetes 29158, 21.1 3890, 30.8 25268, 20.2 <0.001
Dyslipidaemia 52057, 37.8 5007, 39.7 47050, 37.6 <0.001
Epilepsy 1050, 0.8 207, 1.6 843, 0.7 <0.001
Fibromyalgia 1266, 0.9 124, 1.0 1142, 0.9 <0.001
Hypertension 73250, 53.1 7626, 60.4 65624, 52.4 <0.001
Ischaemic heart disease 11401, 8.3 1745, 13.8 9656, 7.7 <0.001
Neuropathies 5067, 3.7 575, 4.6 4492, 3.6 <0.001
Peripheral artery disease 3888, 2.8 916, 7.3 2972, 2.4 <0.001
Ulcers 4274, 3.1 444, 3.5 3830, 3.1 0.005
SD standard deviation, PHC primary healthcare, BMI body mass index, MEDEA socioeconomic index, (U unknown urban area, U# urban areas), R rural area,
GFR glomerular filtration rate, COPD chronic obstructive pulmonary disease
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ischaemic heart disease history (cases n = 1745, 13.8 %
and controls n = 9656, 7.7 %), all statistically significant
(p < 0,001). Also, the comedications at baseline showed
differences (cardiac therapy for cases n = 2448, 19.4 %
and for controls n = 15,565, 12.4 % and insulins cases
n = 1276, 10.1 % and controls n = 4796, 3.8 %) but not for
antidementia drugs (cases n = 2020, 16.0 % and controls
n = 20,451, 16.3 %) and coxibs and oxicams (cases n =
2020, 16.0 % and controls n = 20,451, 16.3 %).
During the study period 2,865 (22.7 %) cases were ex-
posed to AED (ATC classification N03) and 19,406
(15.5 %) were controls. Cases were more frequently ex-
posed to all AED than controls (Table 3), except for
pregabalin (38.4 % cases vs. 44.4 % controls exposed, p <
0.001). The drugs with the highest proportions of pa-
tients exposed were pregabalin (8,861 39.8 %) and gaba-
pentin (9,720 43.6 %).
The effect of the AED exposure was adjusted for dif-
ferent baseline variables for the regression models
(Fig. 2). Global exposure to AED showed a risk of 1.06
(95 % CI 0.99–1.13, p = 0.057) of ischaemic stroke and
above all, the exposure to levetiracetam [(ORadj 3.3
CI95 % 2.8-4)], phenytoin [(ORadj 1.5 CI95 % 1.2–1.9)]
and valproic acid [(ORadj 1.3 CI95 % 1.1–1.6)] did. Past
exposure to lamotrigine [(ORadj 1.6 CI95 % 1.5–1.7)],
phenobarbital [(ORadj 2.1 CI95 % 1.3–3.2)] and pheny-
toin [(ORadj 1.6 CI95 % 1-2.5)] showed a risk but only le-
vetiracetam [(ORadj 4.1 CI95 % 3.3–5.2)] and valproic
acid [(ORadj 1.4 CI95 % 1.1–1.9)] showed it when asses-
sing current use. When the effect of AED in monother-
apy was analysed, only levetiracetam (ORadj 5.1 CI95 %
3.7–6.9) was associated with a high risk of ischaemic
stroke.
Discussion
Most studies assessing risk of stroke with use of AED
were cohort studies which did not analyse different
times of exposure as in our study, our research analyse
global, past, current and current monotherapy exposures
through a case-control design. We found that global ex-
posure to AED was not significantly associated to ischae-
mic stroke (OR 1.06, CI95 % 0.998–1.128) [8–17].
Among the classic AED (phenobarbital, phenytoin, val-
proic acid, carbamazepine and clonazepam) only the








Acetic acid derivatives 58,208, 42.2 5652, 44.8 52,556, 42.0 < 0.001
Analgesics (metamizol and paracetamol) 109,801, 79.6 10,771, 85.4 99,030, 79.1 < 0.001
Anti-dementia agents 8907, 6.5 861, 6.8 8046, 6.4 0.080
Antidepressants 39,851, 28.9 4465, 35.4 35,386, 28.2 < 0.001
Antihypertensive agents 3774, 2.7 576, 4.6 3198, 2.6 < 0.001
Antithrombotic drugs 39,951, 29.0 8613, 68.3 31,338, 25.0 < 0.001
Antipsychotics 20,024, 14.5 2361, 18.7 17,663, 14.1 < 0.001
Anxiolytics 62,234, 45.1 6536, 51.8 55,698, 44.5 < 0.001
Beta-blockers 18,022, 13.1 2864, 22.7 15,158, 12.1 < 0.001
Blood glucose-lowering drugs 20,733, 15.0 2896, 23.0 17,837, 14.2 < 0.001
Calcium channel-blockers 18,013, 13.1 2448, 19.4 15,565, 12.4 < 0.001
Cardiac therapy 13,233, 9.6 2251, 17.8 10,982, 8.8 < 0.001
Coxibs and oxicams 22,471, 16.3 2020, 16.0 20,451, 16.3 0.369
Diuretics 28,656, 20.8 3794, 30.1 24,862, 19.8 < 0.001
Gastrointestinal tract 2505, 1.8 491, 3.9 2014, 1.6 < 0.001
Hypnotics and sedatives 23,208, 16.8 2607, 20.7 20,601, 16.4 < 0.001
Insulins 6072, 4.4 1276, 10.1 4796, 3.8 < 0.001
Lipid-modifying agents 42,897, 31.1 6119, 48.5 36,778, 29.4 < 0.001
Opioids (phentanil, buprenorphine and tramadol) 33,489, 24.3 3672, 29.1 29,817, 23.8 < 0.001
Propionic acid derivatives 93,012, 67.5 8839, 70.1 84,173, 67.2 < 0.001
Psychostimulants, ADHD-agents and nootropics 11,948, 8.7 1390, 11.0 10,558, 8.4 < 0.001
Renin-angiotensin agents 54,778, 39.7 6657, 52.8 48,121, 38.4 < 0.001
Other anti-inflammatories (glucosamine and chondroitin sulphate) 17,342, 12.6 1433, 11.4 15,909, 12.7 < 0.001
ADHD attention deficit hyperactivity disorder
Giner-Soriano et al. BMC Neurology          (2021) 21:208 Page 5 of 9
Table 3 Exposure to antiepileptic drugs
N, % Total N = 22,271 Cases N = 2,865 Controls N = 19,406 p-value
Carbamazepine exposure 1238, 5.6 169, 5.9 1069, 5.5 0.407
Current exposure 321, 1.4 52, 1.8 269, 1.4
Past exposure 202, 0.9 32, 1.1 170, 0.9
Monotherapy 140, 0.6 15, 0.5 125, 0.6
Clonazepam 4675, 21.0 570, 19.9 4105, 21.2 0.128
Current 1089, 4.9 135, 4.7 954, 4.9
Past 1019, 4.6 124, 4.3 895, 4.6
Monotherapy 525, 2.4 52, 1.8 473, 2.4
Gabapentin 8861, 39.8 1138, 39.7 7723, 39.8 0.951
Current 1814, 8.1 296, 10.3 1518, 7.8
Past 1994, 9.0 244, 8.5 1750, 9,0
Monotherapy 1060, 4.8 177, 6.2 883, 4.6
Lamotrigine 575, 2.6 94, 3.3 481, 2.5 0.012
Current 191, 0.9 38, 1.3 153, 0.8
Past 146, 0.7 21, 0.7 125, 0.6
Monotherapy 72, 0.3 14, 0.5 58, 0.3
Levetiracetam 654, 2.9 231, 8.1 423, 2.2 <0.001
Current 383, 1.7 166, 5.8 217, 1.1
Past 62, 0.3 10, 0.3 52, 0.3
Monotherapy 187, 0.8 90, 3.1 97, 0.5
Oxcarbazepine 556, 2.5 83, 2.9 473, 2.5 0.137
Current 149, 0.7 27, 0.9 122, 0.6
Past 131, 0.6 20, 0.7 111, 0.6
Monotherapy 66, 0.3 11, 0.4 55, 0.3
Phenobarbital 520, 2.3 85, 3.0 435, 2.2 0.018
Current 205, 0.9 39, 1.4 166, 0.9
Past 124, 0.6 28, 1.0 96, 0.5
Monotherapy 58, 0.3 10, 0.3 48, 0.2
Phenytoin 610, 2.7 128, 4.5 482, 2.5 <0.001
Current 232, 1.0 49, 1.7 183, 0.9
Past 121, 0.5 25, 0.9 96, 0.5
Monotherapy 96, 0.4 17, 0.6 79, 0.4
Pregabalin 9720, 43.6 1100, 38.4 8620, 44.4 <0.001
Current 1829, 8.2 239, 8.3 1590, 8.2
Past 2586, 11.6 285, 9.9 2301, 11.9
Monotherapy 1058, 4.8 119, 4.2 939, 4.8
Topiramate 1088, 4.9 168, 5.9 920, 4.7 0.010
Current 176, 0.8 36, 1.3 140, 0.7
Past 285, 1.3 45, 1.6 240, 1.2
Monotherapy 77, 0.3 9, 0.3 68, 0.4
Valproic acid 1037, 4.7 192, 6.7 845, 4.4 <0.001
Current 367, 1.6 92, 3.2 275, 1.4
Past 214, 1.0 28, 1.0 186, 1.0
Monotherapy 175, 0.8 39, 1.4 136, 0.7
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exposure to phenytoin and valproic acid showed a risk
for ischaemic stroke that was even higher for current ex-
posure in the case of valproic acid. The highest risk for
these classics was for the old phenobarbital past expos-
ure showing an adjusted risk of 2.0 (CI95 % 1.3–3.2). Re-
garding phenytoin and valproic acid, they demonstrated
higher risk of stroke when compared to carbamazepine
in the study of Hsieh et al. [16]. A pharmacokinetic ex-
planation, regarding the role as potent inducers of cyto-
chrome P450 enzymes (involved in cholesterol synthesis)
of carbamazepine or phenytoin could substantially in-
crease the risk of cardiovascular and cerebrovascular dis-
ease [28]. When compared to the new AED, only past
exposure to lamotrigine (ORadj 1.6 CI95 % 1.5–1.7)
showed a risk for stroke. Renoux et al. analysing the past
exposure to AED did not find an increased risk of is-
chaemic stroke (RR 0.89, CI95 % 0.78–1.01) [15]. In the
case of those AED which were associated to an increased
risk of stroke for the past exposure but not for the
current, we are not able to conclude if this higher risk
was caused by the epilepsy itself or by the drug exposure
[7, 18, 19, 29].
Nevertheless, measuring current exposure to AED may
be more accurate in order to assess the real increase of
risk of ischaemic stroke caused by these drugs. In our
study, levetiracetam exposure was associated with the
highest risk of stroke [OR adj 3.3 (CI95 % 2.8- 4.0)] even
higher when assessing monotherapy exposure [OR adj
5.1 (CI95 % 3.7–6.9] was assessed. Levetiracetam shows
a risk for stroke when handle the indication bias taken
only first incident stroke cases excluding prescriptions in
the same month of the index date. To be considered that
levetiracetam is used for the most severe and for refrac-
tory epilepsies when other AED fail, information not
available in our database, what could address a risk of
the epilepsy itself. We have not found any studies with
similar results for levetiracetam. Deeper studies have to
be conducted, analysing the AED indications what could
be relevant to support our results.
Clonazepam is a benzodiazepine usually used as an
“add-on” medication for people who continue to have
seizures while taking other seizure medicines. Not hav-
ing diagnosis linked to its prescription can refer to its
use for psychiatric disorders and not really to prevent
seizures. It can also be prescribed as “if needed” which
wouldn’t reflect its use.
The AED studied with higher prevalence of use in our
population were gabapentin and pregabalin, drugs which
have other indications with a more frequent use than
epilepsy; both are authorized for neuropathic pain and
Fig. 2 Risk of ischaemic stroke according to different exposures to antiepileptic drugs
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pregabalin is also authorized to treat anxiety disorders,
which are more prevalent disorders than epilepsy. None
of these drugs show a risk for stroke for the different ex-
posures estimated.
Among AED those with a mainly use in our country
for epilepsy, phenytoin and valproic acid, showed a glo-
bal risk [OR adj 1.5 (CI95 % 1.2–1.9)] [OR adj 1.34
(CI95 % 1.1–1.6)] which are not maintained in the past
exposures meanwhile lamotrigine and phenobarbital
showed a risk for the past exposure [OR adj 1.58
(CI95 % 1.5–1.7) and OR adj 2.08 (CI95 % 1.3–3.2) re-
spectively], thus we cannot rule out that the epilepsy it-
self is increasing stroke risk.
One of the main limitations of our data is the lack of
association between a drug prescription and a diagnosis
registered, or the lack of registry of the severity of epi-
lepsy. We cannot know the diagnosis which led to the
AED prescription, not only seizures but also the possibil-
ity of other diagnosis that could lead to AED prescrip-
tion such as tumour, hypoxia, and neuropathic pain,
among others. The main cause of seizures in the elderly
is stroke (52.3 %), [30] what can point to an indication
bias in our study, we have even tried to handle it by ex-
cluding those patients a first stroke episode and exclud-
ing those AED prescriptions in the same month of the
index date. There are no diagnostic images available in
our database, so we were not able to examine a possible
ischemic lesion by imaging study in either the controls
or the cases, thus, this remains as a limitation inherent
to our study.
Conclusions
Drugs used for other conditions than epilepsy were the
most used AED (pregabalin, gabapentin). They didn’t
show a risk for stroke.
An inherent risk of the epileptic condition for stroke
cannot be dismissed with the present study results, but
no link between drugs and diagnosis in our database
made this a limitation in our research.
Levetiracetam shows a risk for stroke global exposure,
current and also monotherapy.
Even our effort for handling the indication bias the
lack of data regarding the diagnosis, severity and kind of
epilepsy for it use should be address with further
research focus on this active substance.
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